News & Press Releases

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“ 

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing. 

New York Law Journal published an article written by Jason P.W. Halperin, Robert Kidwell, Ellen Shapiro, and Kristina Van Horn about the New York State Senate passing the Twenty-First Century Anti-Trust Act (SB 335), an amendment to New York’s General Business Law. In the article, the attorneys outline the biggest implications of the proposed law, including what would be the most comprehensive pre-merger notification program of any state in the country.

Mintz secured a rare trademark temporary restraining order (TRO) on behalf of IYO, Inc. against OpenAI, Sam Altman, Sir Jony Ive, and IO Products, Inc. The order temporarily bars the defendants from using the trademark associated with their new product launch. 

International Life Sciences Chair Cheryl Reicin was a guest on The Deal's “Drinks with The Deal” podcast, where she discussed her career journey and shared advice for those looking to make an impact in the field.